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Phase H and pharmacokinetic study of lobaplatin in patients with
relapsed ovarian cancer
JA Gietema', G-J Veldhuis', H-J Guchelaar', PHB Willemsel, DRA Uges', A Cats', H
Boonstra3, WTA van der Graaf', D Th Sleijferl, EGE de Vnres' and NH Mulderl
Departments of'Medical Oncology, 2Hospital Pharmacy and 3Oncologic Gynaecologv, L'niversity Hospital Groningen,
The Netherlands.
Summary In phase I studies. lobaplatin showed activity in ovarian cancer patients pretreated with platinum.
A phase II trial with lobaplatin was performed in patients with refractory or relapsed ovarian cancer to define
activity and pharmacokinetics. Twenty-two patients were treated with lobaplatin administered as an intra-
venous bolus every 4 weeks. Dependent on creatinine clearance (CRCL) patients received 30 or 50 mgm-2
lobaplatin as the starting dose. Twenty-two patients received 78 courses (median 3, range 1-6). In eight
patients total platinum (TPt) in plasma and urine, free platinum (FPt) in plasma ultrafiltrate (both measured
by atomic absorption spectrometry) and lobaplatin in plasma ultrafiltrate measured (by high-performance
liquid chromatography) were measured. Toxicity was confined to mild nausea and vomiting, mild
leucocytopenia (WHO grade 3 in 18% of the courses), and renal function-related thrombocytopenia (WHO
grade 3 4 in 53% of the courses). A correlation was found between CRCL and reduction in platelet count
(r = -0.77; P<0.0l). No renal toxicity was encountered. Five of 21 evaluable patients (24%) achieved a
response (four complete remissions and one partial remission). Remissions occurred mainly in patients who
relapsed more than 6 months after primary treatment. The median survival from start of lobaplatin treatment
was 8 months. The mean areas under the curve (AUCs) were 4.2 ± 0.5, 3.0 ± 0.6. and 3.2 ± 1.1 h mgl-' for
TPt, FPt and lobaplatin respectively. The free platinum fraction (FPt TPt) was initially very high, indicating
low protein binding. FPt was essentially present as intact lobaplatin. Four hours after infusion 54 ± 5% and
24 h after infusion 74 ± 3% of the lobaplatin dose was excreted in the urine. In conclusion. lobaplatin is a
platinum compound with anti-tumour activity in patients with relapsed ovarian cancer, especially in those who
have platinum-sensitive tumours. The main toxicity of lobaplatin is thrombocytopenia and its dose should be
corrected according to renal function.
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Over the last decade, treatment of patients with ovarian
cancer has been dominated by cisplatin-containing regimens
(Neijt et al., 1984; Williams et al., 1985; Omura et al., 1986).
Combinations of cisplatin with one single alkylating agent
give equivalent results to three- or four-drug schedules, but
appear to be less toxic (Neijt et al., 1987). In recent years, the
development of new drugs has been directed towards the
development of platinum analogues that are equipotent but
less toxic than the parent compound. Carboplatin has
emerged as leading analogue in this respe-t with reduced
nephrotoxicity, gastointestinal toxicity and neurotoxicity
(Calvert et al., 1982; Evans et al., 1983). Myelotoxicity,
especially thrombocytopenia. has been found to be the dose-
limiting toxicity of carboplatin. Especially in ovarian cancer,
carboplatin appears to have equivalent activity to cisplatin
(Alberts et al., 1992; Swenerton et al., 1992).
An important direction in current research is to find new
cisplatin analogues that are less toxic and more effective than
second-generation analogues such as carboplatin. One of
these compounds might be lobaplatin (1,2-diamminomethyl-
cyclobutane-platinum (II)-lactate, D-19466) (Figure 1).
Lobaplatin has a greater anti-tumour effect in vitro towards
B16 melanoma and AH13s hepatoma than cisplatin (Voegeli
et al., 1990). This was also implied by experiments performed
in two cell lines and their cisplatin-resistant sublines. In a
small-cell lung carcinoma cell line (GLC4) and its resistant
subline (GLC4-CDDP), lobaplatin showed full cross-
resistance, whereas in another line, a human embryonal
cancer cell line (Ntera2/DI), and its cisplatin-resistant subline
(tera-CP), lobaplatin demonstrated no cross-resistance (Mei-
jer et al., 1992). In vivo, in mice bearing P388 leukaemia,
administration of lobaplatin resulted in a greater increase in
lifespan than cisplatin or carboplatin. In a cisplatin-resistant
P388 tumour in which neither cisplatin nor carboplatin was
able to inhibit the proliferation after transplantation, the
survival of the animals was significantly prolonged by loba-
platin (Voegeli et al., 1990). These preclinical in vitro and
animal data suggest that the anti-tumour activity of loba-
platin is different from that of cisplatin and carboplatin and
might be not cross-resistant.
In phase I studies with lobaplatin administered by different
schedules (daily bolus infusion for 5 days, 72h continues
infusion and single bolus infusion) its main toxicity appeared
to be on the bone marrow, and especially concerned throm-
bocytopenia (Fiebig et al., 1991; Gietema et al., 1993a,b).
Gastrointestinal toxicity was mild and renal toxicity did not
occur. In the daily bolus infusion for 5 days schedule the
thrombocytopenia was clearly related with the renal function
of the individual patients, resulting in different maximal
tolerated dosages for different renal function cohorts
(Gietema et al., 1993a). In a one day bolus and a continuous
infusion schedule the toxicity pattern was similar to that of a
5 day regimen. The optimal dosages of lobaplatin in the three
outlined schedules for patients with a creatinine clearance
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(CRCL) above 80 ml min-' were between 45 and 70 mg m-2.
In phase I studies with lobaplatin tumour responses were
seen in several patients with (partial) platinum-resistant
ovarian carcinoma (Gietema et al., 1993a,b).
The promising results from the phase I studies prompted
us to undertake a phase H study using a single bolus infusion
of lobaplatin in patients with residual or relapsed ovarian
cancer after treatment with a platinum-based regimen. In
addition, detailed analysis of the pharmacokinetics of loba-
platin was performed.
Patem and
Twenty-two patients with FIGO stage III or IV ovarian
cancer and measurable tumour lesions, recurrent or residual
after pnor platinum-based combination chemotherapy, were
entered into this phase II study. To be eligible for this study,
patients had to fulfil the following criteria: (a) age 18-75
years; (b) an estimated life expectancy of > 3 months; (c) a
WHO performance status of < 2; (d) complete recovery from
all toxic effects from prior treatments with a treatment-free
interval of at least 4 weeks; (e) adequate bone marrow func-
tion (leucocyte count > 3 x109 1-' and platelet count
> I00 x 109 -1; (f) serum creatinine level < 135jmol 1-' and
a creatinine clearance (CRCL) > 40 ml min '; (g) serum
bilirubin < 30izmol 1'. This protocol was approved by the
Medical Ethical Committee of the University Hospital Gron-
ingen, The Netherlands. Informed consent was obtaied from
all patients after they were informed of the investigational
nature of this treatment.
Lobaplatin was supplied by ASTA Medica (Frankfurt,
Germany). The dose of lobaplatin was dissolved in sterile
water and reconstituted in 100 ml of 0.9% sodium chloride.
Lobaplatin was administered as an i.v. bolus once every 4
weeks. The starting dose of lobaplatin depended on renal
function expressed as creatinine clearance (CRCL). Patients
with a CRCL > 80 ml min-' started with 50 mg m2 loba-
platin. Patients with a CRCL <80 ml min ' start with
30 mg m2. Dose escalation with 10 mg m2 was performed
in case of haematological toxicity < WHO grade 2. In the
case of WHO grade 4 haematological toxicity the dose of the
next cycle was de-escalated with 10 mg m-2. For WHO grade
3 myelotoxicity no changes were made. This dose
modification scheme would allow every patient to be treated
on the maximum tolerated dose level of lobaplatin. Toxicity
was evaluated according to WHO criteria Prophylactic
antiemetics, i.e. 5-HT3 antagonists, were administered to all
patients.
To be evaluable for response, patients had to receive at
least two courses of lobaplatin. Tumour evaluations were
performed at entry and after every two treatment cycles. A
complete response (CR) was defined as a disappearance of all
evidence of the tumour and no development of new lesions
for at least 4 weeks. A partial response (PR) was defined as a
decrease of at least 50% in the sum of the products of the
largest perpendicular diameters of all measurable lesion.
Stable disease meant a decrease within 50% or an increase of
less than 25% in any measurable lesions. Progressive disease
was defined as an increase of more than 25% of the lesions
or the occurrence of any new lesions. Measurements of CA-
125 were only used to support these response data. Patients
were removed from the study in case of progressive disease
and for severe non-haematological toxicity (WHO grade
3-4). A maximum of six cycles were given.
At entry and during each 28 days course, complete blood
cell count, electrolytes, liver and renal function and glucose
were measured on the treatment day and on days 14, 21, and
28. Twenty-four hour urinary creatinine clearances were per-
formed twice before study entry, before each course and after
the last course of lobaplatin.
Pharmacokinetic analysis was performed in eight con-
secutive patients during the first course of lobaplatin
50 mg m-2. Blood samples were drawn on ice from the non-
infused arm in heparinised glass tubes (Venoject, Omnilabo,
Breda, The Netherlands) before infusion and at t =0 (just
after end ofinfusion) and 5, 10, 15, 30, 45, 60, 90, 120, 180,
240, 300, 720 and 1440 min after end of lobaplatin infusion.
Samples were immediately centrifuged. Ultrafiltrate samples
were prepared by centrifugation over an Amicon Centifree
microparitition system provided with a YMT cut-off filter
(MW>30000Da) (Product No. 4104, Amicon, Oosterhout,
The Netherlands). The plasma and ultrafiltrate samples were
stored at -20'C until analysis. Portions of urine were col-
lected at six appropriate intervals during 24 h following the
infusion and stored at - 20'C until analysis. Platinum con-
centration in the samples was determined by flameless atomic
absorption spectrometry (AAS) (Leroy et al., 1977). The
amount of platinum was determined using a model AA1275
atomic absorption spectrophotometer with a GTA9S graphite furnace and autosampler unit (Varian Techtron, Mulgrave, Victoria, Australia). Absorption was measured at 265.9 nm
with a spectral bandwidth of 0.5 nm and deuterium back-
ground correction. This method has a limit of detection for
platinum of 0.1 mg l-'. Lobaplatin was determined by a
high-performance liquid chromatographic (HPLC) method
which has been described previously (Guchelaar et al., 1992).
This method has a limit of detection of lobaplatin of
0.2 mg 1-'. The plasma concentration-time data for the indi-
vidual patients were subjected to analysis using a computer
program for pharmacokinetic linear curve fitting (MWPharm, Mediware, Groningen, The Netherlands). The
area under the plasma concentration-time curve (AUC) was
calculated using the model-independent trapezoidal rule.
Regression analysis in this study was calculated by the
method of least squares. Statistical analysis was performed with the Student's t-test. Only two-tailed P-values<0.05
were considered to be significant.
Results
Patients
The characteristics of patients entered in this phase II trial
are outlined in Table I. The 22 patients received 78 courses
(median 3, range 1-6). All patients were evaluable for tox-
icity and 21 also for response. Nineteen patients had been
treated with one previous chemotherapy schedule, three
patients had received two previous schedules.
Eight patients achieved a partial (n = 3) or complete res-
ponse (n=5) on previous therapy which lasted for more than
6 months. These patients were considered clinically platinum
sensitive. The outcome of prior treatment of the remaining 14
patients was progressive disease (n = 4); stable disease
(n = 5); or relapse within 6 months after a partial response (n = 5). The last patient group was considered to be clinically
platinum resistant. The median platinum-free intervals of the
platinum-sensitive and the platinum-resistant group were 30
months (range 7-60) and 2 months (range 2-6) respectively.
Response and survival
Twenty-one patients were evaluable for response as one
patient had progressive disease during the first course of
lobaplatin. There were four complete responses and one par-
tial response. The overall response rate was 24% (95%
confidence interval 8-47%). Details of responders are sum-
marised in Table II. Most responses occurred in pelvic
masses; in two patients the response was cytologically
verified. Remissions occurred more frequently in patients who were considered clinically platinum sensitive than in
those who were platinum resistant: four (50%) vs one (8%)
respectively. Median response duration was 10 months (range 8-13+ months). Two patients had stable disease and 14
patients had progressive disease during lobaplatin treatment.
The median survival from the date of starting chemotherapy with lobaplatin was 8 months (range 3-28).
Survival of patients who were considered clinically platinum
sensitive (n = 8) and of patients who were clinically platinum
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resistant (n = 14) are depicted in Figure 2. The median sur-
vival of platinum-sensitive patients has not yet been reached,
whereas the median survival of the platinum resistant
patients was 7 months.
Toxicity
As expected from phase I studies, myelotoxicity was the
major and dose-limiting toxicity of lobaplatin. In 11 patients
the lobaplatin dose could be escalated after the first course,
whereas in two patients the does had to be de-escalated. The
haematological toxicity data are detailed in Table III.
Because the treatment protocol provided dose escalation until
grade 3 haematological toxicity, 18 of the 22 patients
developed WHO grade 3/4 myelosuppression. Short-lived
thrombocytopenia WHO grade 3/4 occurred in 18 patients
during 53% of the administered courses. In four (18%)
patients this was associated with WHO grade 3
leucocytopemna. None of the patients experienced grade 4
leucocytopenia. The platelet nadir occurred mostly between
day 14 and 21 and in the majority of patients lasted less than
Table I Characteristics of patients treated with lobaplatin
Nwnber of patients
1 week. All patients recovered from haematological toxicity
within 28 days after lobaplatin admiimstration. Seven patients
required prophylactic platelet transfusions during grade 4
thrombocytopenia. There were no signs of clinical bleeding
during thrombocytopenia. As anticipated from phase I
studies with lobaplatin, we suspected a relation between
thrombocytopenia and renal function. For 15 patients treated
with 50mgm-2 lobaplatin as first course, we observed (see
Figure 3) a significant correlation between CRCL and
percentage reduction in platelet count (r = -0.77; P<0.01).
There were no episodes of neutropenic fever. Eleven patients
developed symptomatic anaemia during lobaplatin treatment;
this required red blood cell transfusions in six patients. In
patients who received 4-6 courses lobaplatin (n = 10), there
were signs of cumulative toxicity mainly concerning the
number of platelets and erythrocytes.
Non-haematological toxicity was confined to mild nausea
and vomiting despite the use of prophylactic 5-HT3 receptor
antagonists in 14/22 patients (64%). No changes in renal
function (expressed as 24h CRCL) were observed during
treatment with lobaplatin. The mean CRCL before start and
after the last course was 90± 21 and 88 ± 23 ml min-'
respectively (NS). Furthermore, no neurotoxicity, ototoxicity,
hepatic toxicity or alopecia was encountered during treat-
ment with lobaplatin.
Median age (range) (years)
WHO performance status
0-1
2
Ovarian cancer FIGO stage
III
IV
Previous treatment
One platinum-containing regimen
Two platinum-containing regimens
Platinum treatment-free interval
t 6 months
>6 months
Mean creatinine clearance at study entry
CRCL > 80 ml min- '
CRCL < 80 ml min- '
Starting dose of lobaplatin
50 mg m-2
30mgm-'
56 (27-69)
17
5
16
6
19
3
14
8
90 (range 52-126)
15
7
15
7
Fuwe 2 Survival of patients treated with lobaplatin. Dotted
line, platinum-sensitive patients (n = 8); solid line, platinum-
resistant patients (n = 14).
Tabl Summary of responding patients
Nwnber of prior Platinwn-free Response to CA 125 with Duration of
Patient Age platinwn-containing interval Evaluable twnour lobaplatin lobaplatin treatment response Survival
no. (Years) schedules (months) lesion (method) treatment Before After (months) (months)
1 42 2 7 Vagina-top mass CRa 70 45 8 17
(CT scan)
2 57 1 34 Pelvic mass PR 44 36 12 26+
(CT scan)
3 43 1 48 Vagina-top mass CR 18 5 13+ 15+
(ultrasound scan)
4 51 1 60 Pelvic mass and multiple CR 144 3 10+ 12+
liver metastases (CT scan)
5 53 1 3 Vagina-top mass CRa 35 3 8+ 10+
(ultrasound scan)
aCytologically verified complete response.
Table III Haematological toxicity: number of courses associated with WHO toxicity grade
WHO toxicity grades
1 2 3 4 1 2 3 4 1 2 3 4
Dose (mgm 2' No. of patients TVo. of courses Leucocvtes Thrombocytes Haemoglobin
20 2 3 1 0 0 0 0 3 0 0 0 0 0 0
30 11 19 6 5 1 0 2 1 3 3 3 5 0 0
40 11 11 3 5 2 0 1 1 5 4 2 5 0 0
50 15 33 5 11 7 0 4 3 11 8 9 6 3 0
60 5 12 6 4 0 0 1 3 3 1 6 3 0 0
1.0
0.80
2 0.60
._>
" 0.40
Cl,
12
Months
24 36Pharmnacokinetics
Pharmacokinetic analysis was performed during the first
course in eight consecutive patients treated with 50 mg m-
lobaplatin. A concentration-time profile of total platinum
(TPt). ultrafiltrable platinum (FPt) and native lobaplatin of a
representative patient is shown in Figure 4. Lobaplatin con-
centrations were corrected for difference in molecular weight
in order to make comparisons with atomic TPt and FPt
possible. In all patients levels were non-detectable from 12 h
after infusion. Additional pharmacokinetic parameters are
summarised in Table IV. An open two-compartment model
resulted in the best fit for TPt, FPt and native lobaplatin. In
Figure 5, the free Pt fraction (FPt/TPt) is depicted for the
period at which both species could be accurately measured
(t = 240 min). This ratio is initially very high and decreases
gradually, indicating low protein binding. The fraction
lobaplatin/FPt is also shown in Figure 5 and reveals that free
platinum is mainly present in the form of native lobaplatin.
Elimination of lobaplatin is characterised by rapid urinary
excretion, as shown in Figure 6. Calculation of the renal
platinum clearance based on measured urine samples
amounted initially to a mean renal platinum clearance of
104 ± 30 ml min-' (the mean CRCL of these eight studied
patients was 100 ± 12 ml min-').
We studied the possible relationship between CRCL and
drug clearance. However, no correlation could be detected
between CRCL and plasma clearance of either TPt, FPt or
lobaplatin. Furthermore, no correlation was observed
between the AUC of TPt, FPt, lobaplatin and percentage
reduction in platelet count after the first course of lobaplatin
respectively.
obaplaUn in ovaran cance
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Figwe 4 Concentration-time profile of a representative patient
treated with 50mgm-2 lobaplatin. *. TPt; A. FPt; 0. lobap-
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Figwe 5 (a) The mean fraction FPt TPt for eight patients
(mean ± s.d.). (b) The mean fraction native lobaplatin FPt for
160 eight patients (mean ± s.d.).
Fugwe 3 Correlation between creatinine clearance (CRCL) and
percentage reduction in platelet count for the 15 patients treated
with 50mgm2 lobaplatin as first course (r= -0.77; P<0.01).
Table IV Pharmacokinetic parameters (mean ± s.d.) of lobaplatin
(eight patients)
Total Pt in plasma Lobaplatin in
platinwn ultra-filtrate plasma
(TPt) (FPt) ultrafiltratea
C..x, (mglI-') 3.3 _1.1 3.0_0.9 2.6+± 1.i
t,2. (min) 18.6 8.8 5.4 2.7 10.6±9.0
t,1 (min) 142 46 61.2 6.9 93.3 ± 23.9
V.*SS (1) 23.6 6.0 18.5 3.5 24.5 ± 9.3
AUC (hmgl-') 4.2±0.5 3.0 0.6 3.2± 1.1
CLp (Ih-') 9.9± 1.1 14.4± 3.6 14.6± 7.0
'Corrected for platinum content.
0
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Figwe 6 Cumulative urinary excretion of Pt (per cent of dose
administered) (n = 8).
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Discusion
The current management of patients with ovarian cancer who
have had recurrences after initial platinum-based
chemotherapy is based on a consideration of results of the
initial chemotherapy. Several studies have shown that the
longer the period between completing the first-line and star-
ting the second-line treatment, the higher the response rate
will be of second-line platinum-based chemotherapy (Black-
ledge et al., 1989; Markman et al., 1991). Such platinum-
based therapy will yield response rates up to 40-60% for
treatment-free intervals of more than 6 months (Kavanagh et
al., 1989; Markman et al.. 1991). In patients with clinically
platinum-resistant disease (stable disease as best response or
a partial response lasting less than 6 months) the response
rate of second-line platinum-based therapy will be approx-
imately 10% (Weiss et al.. 1991; Thigpen et al., 1993; Dobbs
et al., 1994). The poor response rates stimulated the develop-
ment of drugs which show activity in platinum-resistant
tumours. From phase I studies with new third-generation
platinum analogue lobaplatin, activity in platinum-resistant
ovarian cancer was suggested (Gietema et al., 1993a,b).
The present phase II study with lobaplatin in patients with
residual or relapsed ovarian cancer after platinum-based
chemotherapy shows an overall response rate of 24%. Most
responses occurred in the patients who were considered
potentially platinum sensitive. Only one of the 14 clinically
platinum-resistant patients responded to lobaplatin treat-
ment. In comparison with the second-line studies quoted
above, the response rates of lobaplatin appear to be of the
same magnitude. The results, especially for the platinum-
resistant group, are disappointing however, especially when
compared with the phase I data of lobaplatin. In two phase I
studies we observed three responses in nine relapsed ovarian
cancer patients (Gietema et al., 1993a,b). Two of these res-
ponding patients could be marked as platinum resistant. A
difference with the current phase II study, however, is the
schedule of administration. In our phase I studies lobaplatin
was given in multiple doses (daily x 5) during one course or
by 72 h continuous infusion. The current bolus infusion of
lobaplatin once every 4 weeks is most convenient for the
out-patient setting but might be less active in terms of drug
exposure. Additional studies with other schedules evaluating
dose intensity will be needed to resolve this issue.
The main adverse effect of lobaplatin concerned the bone
marrow, with thrombocytopenia as dose-limiting toxicity.
While the dose of lobaplatin was escalated in case of mild
toxicity, most patients developed short-lived but profound
grade 3 or 4 thrombocytopenia. As was expected from the
phase I studies, the reduction in platelet counts was related
to renal function. Leucopenia was mild, with no signs of
neutropenic fever. Symptomatic anaemia occurred in several
patients treated with more than four courses of lobaplatin as
a sign of cumulative toxicity. Of importance is the observa-
tion that during this study non-haematological toxicity was
limited to mild nausea and vomiting. No signs of nephrotox-
icity or neurotoxicity was observed. This toxicity profile
makes lobaplatin a good candidate for dose-intensification
strategies.
Pharmacokinetic analysis of lobaplatin measured as total
and free platinum concentrations with AAS and native
lobaplatin with an HPLC method revealed low protein bin-
ding and rapid urinary excretion. Free platinum is mainly
present as intact lobaplatin. It can be stated that the phar-
macokinetic profile of lobaplatin approximately resembles
that of carboplatin (Harland et al., 1984; Gaver et al., 1988).
Plasma elimination data showed that the plasma clearance of
lobaplatin exceeds the CRCL. suggesting that the platinum
species are at least partially actively excreted into the urine.
This is different from carboplatin, which has a platinum
plasma clearance which is similar to the CRCL (Harland et
al., 1984). However, when renal platinum clearance was cal-
culated, this appeared to be similar to CRCL, suggesting that
there might be irreversible tissue binding of lobaplatin.
Because the kidney is the main route of excretion and platelet
toxicity is related to renal function, a relation between loba-
platin plasma clearance and CRCL and a correlation
between lobaplatin AUC and reduction in platelet counts
were expected, as have been previously described for carbop-
latin (Egorin et al., 1984; Calvert et al.. 1989). Probably
because of the small number of patients with only little
variation in CRCL no significant pharmacodynamic relations
could be detected.
In conclusion. lobaplatin showed anti-tumour activity as a
second-line treatment in patients with relapsed ovarian
cancer. Short-lived thrombocytopenia is the dose-limiting
toxicity of lobaplatin and is related to CRCL. No renal
function disturbances were observed during treatment with
lobaplatin. Lobaplatin showed a relatively low protein bin-
ding, with most of unbound platinum present as native
lobaplatin, and a rapid urinary excretion. Additional studies
with lobaplatin also employing other schedules are warranted
to further define its activity in platinum-resistant ovarian
cancer and other cancers.
Acknolegeets
We thank P Bouma and B Greijdanus (Hospital Pharmacy Depart-
ment) for their excellent technical assistance.
References
ALBERTS DS. GREEN' S. HANNIGAN EV. O-TOOLE R. STOCK-
NOVACK D, ANDERSON P. SURWIT EA. MALVLYA WK. NAH-
HAS WA AND JOLLES CJ (1992). Improved therapeutic index of
carboplatin plus cyclophosphamide versus cisplatin plus cyc-
lophosphamide: final report by the Southwest Oncology Group
of a phase III randomized trial in stages III and IV ovarian
cancer. J. Clin. Oncol.. 10, 706-717.
BLACKLEDGE G. LAWTON T. REDMAN C AND KELLY K. (1989).
Response of patients in phase II studies of chemotherapy in
ovarian cancer: implications for patient treatment and the design
of phase II trials. Br. J. Cancer. 59, 650-653.
CALVERT AH. HARLAND SJ AND NEWELL DR. (1982). Early
studies with cis-diammine-1. I-cyclobutane dicarboxylate
platinum II. Cancer Chemother. Pharmacol.. 9, 140-147.
CALVERT AH. NEWELL DR. GRUMBRELL LA. O'REILLY S.
BURNELL M. BOZALL FE. SIDDIK ZH. JUDSON IR. GORE ME
AND WILTSHAW E. (1989). Carboplatin dosage: prospective
evaluation of a simple formula based on renal function. J. Clin.
Oncol.. 7, 1748-1756.
DOBBS SP. GRIBBIN C. CHAN SY AND BESSELL EM. (1994). Second-
line treatment with ifosfamide in patients with ovarian carcinoma
relapsing after treatment with carboplatin. Eur. J. Cancer. 30A,
30-33.
EGORIN MJ. VAN ECHO DA. TIPPING SJ. OLMAN EA. WHITACRE
MY. THOMPSON BW AND AISNER J (1984). Pharmacokinetics
and dosage reduction of cis-diammine (1.1-cyclobutanedicarboxy-
lato) platinum in patients with impaired renal function. Cancer
Res.. 44, 5432-5438.
EVANS BD. RAJU KS. CALVERT AH. HARLAND SJ AND WILTSHAW
E. (1983). Phase II study of JM8. a new platinum analogue. in
advanced ovarian carcinoma. Cancer Treat. Rep.. 67, 997-1000.
FIEBIG HH. MROSS K. HENSS H. AULENBACHER P AND QUEISSER
W. (1991). Phase I study of the new platinum complex D-19466
on a single intermittent schedule (abstract). Eur. J. Cancer. S197
(Suppl. 2).
GAVER RC. COLOMBO N. GREEN MD. GEORGE AM. DEEB G. MOR-
RIS AD. CANETrA RM. SPEYER JL. FARMEN RH AND MUGGIA
FM. (1988). The disposition of carboplatin in ovarian cancer
patients. Cancer Chemother. Pharmacol.. 22, 263-270.
GIETEMA JA. DE VRIES EGE. SLEIJFER D TH. WILLEMSE PHB.
GUCHELAAR H-J. UGES DRA. AULENBACHER P. VOEGELI R
AND MULDER NH. (1993a). A phase I study of 1.2-
diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466;
lobaplatin) administered daily for 5 days. Br. J. Cancer. 67,
396-401.LIobapltn in ovarian cancer
JA Gietema ete
1307
GIETEMA JA. GUCHELAAR H-J. DE VRIES EGE. AULENBACHER P.
SLEIJFER DTH AND MULDER NH. (1993b). A phase I study of
lobaplatin (D-19466) administered by 72 hours continuous
infusion. Anti-Cancer Drugs. 4, 51-55.
GUCHELAAR H-J. UGES DRA. AULENBACHER P. DE VRIES EGE
AND MULDER NH. (1992). Stability of the new anticancer
platinum analogue 1.2-diamminomethyl-cyclobutane-platinum
(II)-lactate (Lobaplatin; D-19466) in intravenous solutions.
Pharm. Res.. 9, 808-811.
HARLAND SJ. NEWELL DR. SIDDIK ZH. CHADWICK R. CALVERT
AH AND HARRAP KR. (1984). Pharinacokinetics of cis-
diammine-l,l-cyclobutane platinum (II) in patients with normal
and impaired renal function. Cancer Res., 44, 1693-1697.
KAVANAGH JJ AND NICAISE C. (1989). Carboplatin in refractory
epithelial ovarian cancer. Semin. Oncol., 16 (suppl. 5), 45-48.
LEROY AF. WEHLING ML. SPONSELLER HL. FRIAUF WS.
SOLOMON RE. DEDRICH RL. LITTERST CL. GRAM TE.
GUARINO AM AND BECHER DA. (1977). Analysis of platinum in
biological materials by flameless atomic absorption spectro-
photometry. Biochem. Med., 18, 184-191.
MARKMAN M. ROTHMAN R, HAKES T, REICHMAN B, HOSKINS W.
RUBIN S, JONES W. ALMADRONES L AND LEWIS Jr JL. (1991).
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J. Clin. Oncol.. 9, 389-393.
MEIJER C. MULDER NH. TIMMER-BOSSCHA. H, MEERSMA GJ AND
DE VRIES EGE. (1992). Relationship of cellular glutathione to the
cytotoxicity and the resistance of seven platinum compounds.
Cancer Res.. 52, 6885-6889.
NEIJT IP. TEN BOKKEL HUININK WW. VAN DER BURG MEL. VAN
OOSTEROM AT. VRIESENDORP R. KOOYMAN CD. VAN
LINDERT AC. HAMERLINCK IV. VAN LENT M AND VAN
HOUWELINGEN IC. (1984). Randomized trial comparing two
combination chemotherapy regimens (Hexa-CAF vs CHAP-5 in
advanced ovarian carcinoma. Lancet, ii, 594-600.
NEIJT IP. TEN BOKKEL HUININK WW. VAN DER BURG MEL, vAN
OOSTEROM AT. WILLEMSE PHB. HEINTZ AP. vAN LENT M.
TRIMBOS JB. BOUMA J AND VERMORKEN JB. (1987). Ran-
domized trial comparing two combination chemotherapy
regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J.
Clin. Oncol.. 5, 1157-1168.
OMURA GA. BLESSING JA. EHRLICH CB. MILLER A. YORDAN E.
CREASMAN WT AND HOMESLEY HD. (1986). A randomized
trial of cyclophosphamide and doxorubicin with or without cis-
platin in advanced ovarian carcinoma. Cancer. 57, 1725-1730.
SWENERTON K. JEFFREY J, STUART G. ROY M. KREPART G. CAR-
MICHAEL J. DROUIN P. STANIMIR R. O'CONNEL G AND
MACLEAN G. (1992). Cisplatin-cyclophosphamide versus carbo-
platin-cyclophosphamide in advanced ovanran cancer: a ran-
domised phase III study of the National Cancer Institute of
Canada Clinical Trials Group tnal. J. Clin. Oncol.. 10, 718-726.
THIGPEN JT. VANCE RB AND KHANSUR T. (1993). Second-line
chemotherapy for recurrent carcinoma of the ovary. Cancer. 71,
1559-1564.
VOEGELI R. SCHUMACHER W. ENGEL J. RESPONDEK J AND HIL-
GARD P. (1990). D-19466 a new cyclobutane-platinum complex
with antitumor activity. J. Cancer Res. Clin. Oncol.. 116,
419-422.
WEISS G. GREEN S. ALBERTS DS. THIGPEN JT. HINES HE. HANSON
K. PIERCE HI. BAKER LH AND GOODWIN JW. (1991). Second-
line treatment of advanced measurable ovarian cancer with ipro-
platin: a Southwest Oncology Group Study. Eur. J. Cancer, 27,
135-138.
WILLIAMS C. MEAD G. MAcBETH F. THOMPSON J. WHITEHOUS
JM. MACDONALD H. HARVEY VJ. SLEVEN ML. LISTER TA AND
SHEPERD JH. (1985). Cisplatin combination chemotherapy versus
chlorambucil in advanced ovarian carcinoma: mature results of a
randomized trial. J. Clin. Oncol.. 3, 1455-1462.